Details for New Drug Application (NDA): 075659
✉ Email this page to a colleague
NDA 075659 describes AFEDITAB CR, which is a drug marketed by Watson Labs and Watson Labs Teva and is included in two NDAs. Additional details are available on the AFEDITAB CR profile page.
The generic ingredient in AFEDITAB CR is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
The generic ingredient in AFEDITAB CR is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
Summary for 075659
| Tradename: | AFEDITAB CR |
| Applicant: | Watson Labs |
| Ingredient: | nifedipine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 075659
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 60MG | ||||
| Approval Date: | Oct 26, 2001 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
